法里西马布用于糖尿病黄斑胀的治疗法里西马布对拉尼比祖马布或阿弗利伯塞普特耐药的患者
Hiromi Ohara1, Yosuke Harada1, Tomona Hiyama1
1Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
Medicina (Kaunas, Lithuania)
|June 28, 2023
概括
法里西马布延长了糖尿病黄斑 (DME) 的治疗间隔,该不耐其他治疗. 转换为法里西马布的患者经历了更长的复发间隔,尽管视力敏度和视网膜厚度的变化并不显著.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病黄斑 (DME) 构成一个重大挑战,往往对标准的抗血管内皮生长因子 (VEGF) 疗法如拉尼比祖马布和阿弗利伯塞普特 (aflibercept) 产生耐火性.
- 法里西马布是一种针对VEGF-A和血管蛋白-2的新型双特异性抗体,为复杂的视网膜疾病提供了新的治疗选择.
研究的目的:
- 评估法里西马布在延长DME患者治疗间隔的疗效,这些患者对先前的抗VEGF治疗有抗性.
- 在这个患者队列中评估法里西马布治疗后的功能性 (最佳校正视力敏度,BCVA) 和解剖学 (中央黄斑厚度,CMT) 结果.
主要方法:
- 一项回顾性观察性研究包括18名耐火性DME患者的18只眼睛,这些患者在预先治疗方案下接受了法里西马布治疗.
- 随访时间至少为4个月,主要结果是≥12周的复发间隔,次要结果包括BCVA和CMT的变化.
主要成果:
- 转换为法里西马布显著延长了平均复发间隔从5.8周到10.8周 (p=0.0005),其中44.4%的患者达到≥12周.
- 曾经注射过三氨醇乙胺的病史和视网膜内层的失调与更短的复发间隔 (<12周) 相关.
- 没有观察到BCVA或CMT的统计学意义上的变化,也没有发生严重的不良事件.
结论:
- 费里西马布在延长对拉尼比祖马布或阿弗利塞普特耐药的DME患者的治疗间隔方面表现出潜力.
- 诸如先前使用triamcinolone或视网膜内层失调等因素可能预测在延长复发间隔方面,反应不那么有利.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
201
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
201
Open Angle Glaucoma: Treatment
481
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
481
Angle Closure Glaucoma: Treatment
577
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
577
Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179


